Heart Drug & Supplement Compendium

BOTTOM LINE

For a cat with confirmed atrial enlargement (B2), the evidence is clear — top of the cardiac-drug ladder. If your cat is already on it, never skipping doses is the best prevention there is.

An enlarged left atrium lets blood swirl slowly and clump into clots; a clot lodging in the hind-leg arteries is ATE — this disease's most feared emergency. Clopidogrel blunts platelet clumping to lower those odds, and the feline randomized FAT CAT trial proved it beats aspirin at preventing recurrence. Hence the ACVIM recommendation to start prevention at stage B2. The fact-check article tells the full story.

FACTS

Research

A feline randomized trial (FAT CAT) proved superiority over aspirin for preventing clot recurrence

Track record

Feline standard for 10+ years (since FAT CAT, 2015)

Caution

Notoriously bitter — use capsules or pill pockets; never stop on your own

Read the full fact-check →

BOTTOM LINE

Irreplaceable once breathing difficulty (stage C) begins. Never stop it over kidney worries on your own — dose-tuning is a tug-of-war to run with your vet.

Heart failure floods the lungs with fluid (pulmonary edema); diuretics pull that water out through urine and make breathing possible again — the backbone of stage C care. The power has a price: less body water means less renal blood flow, so creatinine and BUN rise and potassium drains. Management is about the lowest effective dose balancing "comfortable breathing" against "kidney numbers." Home-counted sleeping breaths are the best gauge of whether it is working — read alongside the breathing-rate card in Care Companion.

FACTS

Research

The established standard for congestive heart failure (stage C) — decades of veterinary practice

Track record

Veterinary standard for 50+ years (furosemide)

Caution

Monitor kidney values and potassium alongside; recheck 3–7 days after starting or increasing · watch hydration

Read the full fact-check →

BOTTOM LINE

For cats in heart failure (stage C), the evidence for trying it is accumulating. But in obstructive HCM (HOCM) it can do harm — this is a drug prescribed by echo findings.

It strengthens contraction and dilates vessels — in dogs, a proven life-extender for heart failure. In cats it is off-label, with retrospective studies suggesting longer survival in CHF. One big string attached: in obstructive HCM (HOCM with SAM), boosting contraction can worsen the obstruction — the echocardiogram decides whether it is used at all. The textbook example of "not every heart drug helps every heart."

FACTS

Research

Off-label in cats — retrospective studies in CHF cats suggest longer survival; no controlled trial

Track record

Licensed for dogs 20+ years · off-label in cats

Caution

Use cautiously or avoid with outflow obstruction (SAM) — the echocardiogram decides

Read the full fact-check →

BOTTOM LINE

The "every HCM cat gets atenolol" era is over. It earns its place only in specific situations — very fast rates or significant outflow obstruction.

It slows the heart and cuts oxygen demand, and for years it was the default HCM prescription. But follow-up studies in asymptomatic cats failed to show slowed progression or longer life, and ACVIM 2020 no longer recommends blanket use. Its remaining role is narrow and clear: significant outflow obstruction (SAM), arrhythmias, or marked tachycardia. If your cat takes it, it is worth asking "why this drug for my cat?" at the next visit — not to stop it, but because knowing the reason is where good management starts.

FACTS

Research

Failed to show delayed progression or survival benefit in asymptomatic HCM (feline observational data) — now reserved for obstruction and arrhythmias

Track record

30+ years of veterinary use · role redefined

Caution

Abrupt stops risk rebound — taper with your vet · caution once in heart failure (C)

Read the full fact-check →

BOTTOM LINE

The first attempt to slow the hypertrophy itself rather than manage symptoms. "Conditional approval" says it best — big hopes, held with careful confidence.

Every cardiac drug so far manages consequences — clots, congestion, obstruction. Rapamycin is the first aimed at the thickening process itself (the mTOR pathway). A small feline randomized trial (RAPACAT) signaled slowed wall-thickness progression, earning a weekly oral formulation US conditional approval (Felycin). The same stage as molidustat in our CKD compendium — promising, with large-scale proof still underway. The fact-check article covers the background.

FACTS

Research

A small feline randomized trial (RAPACAT) signaled slowed wall thickening + US conditional approval (2025) — large-scale proof still accruing

Track record

Conditionally approved in the US in 2025 (weekly oral) — the youngest drug on this list

Caution

An immunosuppressant class — monitor infections and drug interactions with your vet · availability in Korea must be checked

Read the full fact-check →

BOTTOM LINE

Clearly worth starting when systolic stays above 160. Top-tier evidence for protecting the eyes, brain, heart and kidneys.

Hypertension has no symptoms, which makes "symptomatic treatment" a misnomer — unmeasured, it silently damages the eyes (acute blindness), brain, heart and kidneys. Amlodipine dilates vessels directly and lowers pressure reliably; telmisartan adds proteinuria reduction, a bonus in CKD. Both are solidly evidenced in cats. The raw material for the decision is home blood-pressure records — your Care Companion trend chart.

FACTS

Research

Feline hypertension treatment is well-evidenced — amlodipine as standard, telmisartan licensed for cats with trials

Track record

Amlodipine standard for 25+ years · telmisartan (Semintra) licensed for cats 10+ years

Caution

Watch for hypotension during treatment (under 120 with lethargy) · a small creatinine rise after starting is common

Read the full fact-check →

BOTTOM LINE

Generally worth feeding — it is already in renal diets for a reason. Dose and freshness decide whether it does anything.

It works by lowering inflammation and glomerular pressure. In cats the evidence is retrospective (cats on higher-EPA diets lived longer); in dogs, controlled trials show renal protection. No direct feline trial yet — hence the yellow grade — but few supplements come close to this. Human single-ingredient products (iHerb-style) are fine; dose by combined EPA+DHA, and refrigerate to prevent rancidity.

FACTS

Research

Cats: retrospective (higher-EPA diets, longer survival — Plantinga 2005). Dogs: RCT renoprotection. No direct feline RCT

Track record

Standard renal-diet ingredient for 20+ years

Caution

High doses can affect platelets and the gut; discuss stopping before surgery

Read the full fact-check →

BOTTOM LINE

A sure thing for a confirmed deficiency — but HCM is not caused by taurine shortage. For a cat on commercial food, there is no basis to expect benefit from extra.

Taurine owns feline nutrition's greatest success story — in 1987, taurine deficiency was identified as the cause of dilated cardiomyopathy (DCM), food was fortified, and DCM collapsed. That made it the iconic "heart supplement." The catch: that legend belongs to DCM (a dilating disease); HCM (a thickening disease) has nothing to do with taurine deficiency. Commercial diets already contain plenty, and extra has no demonstrated benefit. Cats on raw or home-cooked diets are the separate, legitimate deficiency question.

FACTS

Research

Curing taurine-deficient DCM is established (historic) — but HCM is not a deficiency disease; no direct evidence

Track record

The 1987 DCM discovery — a legend of feline nutrition

Caution

Excess is fairly benign, but blanket "good for the heart" feeding has no evidence

BOTTOM LINE

Not an evidence-based choice for HCM. Sold alongside taurine and ubiquinol as "good for the heart" — with the thinnest evidence of the three.

Carnitine shuttles fatty acids into the heart muscle's mitochondria, so "fuel supplement for the heart" sounds plausible. Some dogs with DCM showed carnitine-deficiency links and supplementation responses — and that story migrated into cat heart-supplement marketing. The bridge is broken twice: different species (dog→cat) and different disease (DCM, a dilating disease → HCM, a thickening one). No study shows carnitine helping feline HCM. Where carnitine genuinely appears in cats is hepatic lipidosis support — a liver story, not a heart one. It is also an ingredient in heart blends (e.g. Thorne-style combos), so use this entry when judging those.

FACTS

Research

Only scattered dog-DCM case reports (extrapolated across both species and disease) — nothing for feline HCM. Its real feline evidence is in hepatic lipidosis support

Track record

A staple of the human and dog supplement markets

Caution

Excess can cause loose stool and a fishy odor — fairly benign otherwise

BOTTOM LINE

One of the rare herbs with real human clinical trials — whose effect faded as the studies grew. No feline evidence.

Hawthorn is an exception among herbs — it carries not just tradition but actual human trial data. Early small studies and a 2008 Cochrane review suggested modest benefit as an adjunct in chronic heart failure. Then the biggest and longest trial, SPICE (2,681 patients, 2 years), failed to improve the combined outcome of death and hospitalization. Promising while small, fading at scale — the classic supplement-research trajectory.
And all of this is human chronic heart failure. Feline HCM is a disease of a thickened heart, not a weakened one — a different mechanism — and there is not a single cat study.

FACTS

Research

Small human heart-failure studies showed positive signals — but the largest trial, SPICE (2,681 patients, 2 years), failed its primary outcome. No feline studies

Track record

Centuries of European tradition + many human trials (mixed results)

Caution

Possible interactions with cardiac and blood-pressure drugs — check with your vet if your cat is on heart medication

BOTTOM LINE

Three thousand years of tradition is real — but the length of a tradition is not the strength of its evidence. For cats there isn't even safety data.

The bark of the Terminalia arjuna tree, a flagship heart remedy in Ayurveda for nearly three millennia. A handful of small human trials exist, some reporting benefit — but their size and design have kept arjuna out of every mainstream cardiology guideline.
Cats are one step further removed: before efficacy, there is simply no metabolism or safety data. A small amount inside a blend is unlikely to harm — but this ingredient should not be what justifies a product's price or your hopes.

FACTS

Research

A few small human studies with design limitations — not adopted by mainstream cardiology, no feline data

Track record

A flagship heart remedy in traditional Indian medicine

Caution

No feline metabolism or safety data — no basis to feed it on its own

BOTTOM LINE

It wears the label "helps the body adapt to stress" — a category that science has never actually established. The link to the heart is even more distant.

Eleuthero is an "adaptogen" — a class of ingredients said to help the body adapt to stress. The catch: that class itself has never been clinically established. A vague definition makes it a convenient word — anything can join, and anything can be claimed.
There is no heart-specific evidence even in humans. It appears in cardiac blends not because of effect data but because of its traditional "general vitality" image. When you spot this name on a label, count it as one hint that the formula was assembled by image rather than evidence.

FACTS

Research

The adaptogen concept itself is clinically unestablished — no heart-specific evidence even in humans, none in cats

Track record

A traditional tonic in Russia and East Asia

Caution

Specific toxicity reports are rare, but there is no feline data

BOTTOM LINE

The flashiest ingredient in a test tube is not necessarily so inside a body. Cats in particular process plant compounds through different detox pathways than we do — so before efficacy, the missing piece is safety data.

Quercetin, the flavonoid in onions and apples, is a fixture of test-tube antioxidant research. Its weakness is poor absorption when eaten — hence delivery tech like phytosomes (phospholipid complexes), the form used in this product. In humans the evidence sits at small blood-pressure studies.
For cats there is a separate point worth remembering: cats are innately deficient in glucuronidation, a detox pathway (the same reason a fever drug that's safe for humans is lethal to cats). Many plant flavonoids are processed through exactly that pathway — so for cats, the first question about quercetin isn't "does it work" but "has a safe dose been established." The answer, so far, is no.

FACTS

Research

Test-tube and rodent level plus small human studies — no feline data, and cats lack glucuronidation, so flavonoid metabolism differs from humans

Track record

A regular of antioxidant research (mostly in vitro and rodent)

Caution

Cats are deficient in glucuronidation — flavonoid safety unestablished; high-dose standalone feeding not recommended

BOTTOM LINE

Vitamin E that corrects a deficiency is real medicine (pansteatitis). Vitamin E as "antioxidant heart protection" is a story large human trials have already answered — with a no.

Feline vitamin E deficiency is a real disease — pansteatitis, seen with oily-fish-heavy diets, and it is cured by vitamin E. That much is established medicine.
But the hope that "an antioxidant must protect the heart" carries the opposite history: human trials of thousands to tens of thousands of participants (HOPE 2000 and others) found no cardiovascular benefit, and a 2005 meta-analysis of high doses even signaled increased mortality. It is the textbook case of the antioxidant boom collapsing under large-scale testing.
Shines when filling a deficiency, loses its evidence when stacked on top — the pattern running through this whole compendium, in its clearest form.

FACTS

Research

Large human trials (HOPE 2000 etc.) found no cardiovascular benefit; a 2005 high-dose meta-analysis even signaled increased mortality — no feline heart data

Track record

Established for deficiency disease · the antioxidant boom was tested and faded in the 1990s–2000s

Caution

Correcting deficiency and "high-dose supplementation for the heart" are different stories — fat-soluble, so it accumulates

BOTTOM LINE

The brand's quality control (NASC) deserves credit — but no ingredient carries HCM-grade evidence, and most amounts fall short of studied doses.

Coming from Thorne's pet line (now PetDomain), the brand-trust question earns a generous answer. The other question — "does this blend help feline hearts?" — finds none of the 11 ingredients carrying HCM-grade evidence. The amounts sharpen the picture: per 1g scoop, taurine 140mg is a meaningful feline dose, but carnitine 140mg (dog DCM studies used grams) and CoQ10 20mg (human studies use 100–300mg) are symbolic, and magnesium 500mcg / potassium 100mcg are decorative. The herbs — hawthorn, arjuna — are extrapolations from human tradition and small trials. See the taurine, carnitine and ubiquinol cards for each ingredient's full story.

FACTS

Research

No feline clinical evidence for the product — and no ingredient carries direct HCM evidence either

Track record

ThorneVet lineage (now PetDomain) · human Thorne is a top-tier supplement brand

Caution

A multi-herb blend — check interactions with your vet if your cat takes cardiac drugs (clopidogrel etc.)

TYPES & INGREDIENTS

• Taurine 140mgA meaningful feline dose — but HCM is not a deficiency disease (see taurine card)
• L-carnitine 140mgDog DCM studies used grams — symbolic amount (see carnitine card)
• CoQ10 20mgSmall vs 100–300mg in human studies (see ubiquinol card)
• Hawthorn extract 70mgExtrapolated from small human heart-failure studies — no feline data
• Arjuna · eleuthero · quercetinTraditional-medicine and in-vitro level — no feline data
• Vitamin E · iron · Mg · KTrace additions — 500mcg Mg and 100mcg K are nutritionally negligible

BOTTOM LINE

The theory and human data are interesting, but there is not yet evidence of benefit in cats. Safety appears good.

A component of cellular energy production and an antioxidant. Some positive human heart-failure data made it popular for cardiac and senior support, but feline clinical evidence does not exist. In a senior cat already juggling pills, "adding one more harmless thing" is not always the right answer — pill stress is a cost too.

FACTS

Research

No feline clinical evidence — extrapolated from human and in-vitro data

Track record

A human-market staple; veterinary evidence unformed

Caution

Fat-soluble — absorbs better with a fatty meal

BOTTOM LINE

The SOD your cat's body makes matters greatly — but there is no evidence the SOD you feed does that job. A textbook case of marketing borrowing science's name.

SOD is the cell's first-line enzyme against free radicals — its role inside the body is genuine, important science. The problem is *eating* it: SOD is a protein enzyme, and swallowed proteins get broken down by stomach acid and digestive enzymes into amino acids. It never reaches the bloodstream as a working enzyme. Coated products (GliSODin etc.) try to dodge this, but the evidence is rodent-and-small-human-study level — and zero in cats.
One principle to keep: this applies to "edible enzymes" in general, with one exception — digestive enzymes (pancreatin etc.) are *meant* to work inside the gut, no bloodstream required. Those are the enzymes worth swallowing.

FACTS

Research

SOD as an in-body enzyme is real science — oral supplementation has no feline evidence, and enzymes are digested

Track record

A growing human-market trend, now appearing in pet blends

Caution

Fairly benign — but often what justifies a blend's price tag; check this card when you spot it on a label